Thursday, September 11, 2014

George Church and Feng Zhang to keynote inaugural Genome Editing Applications conference

IBC Life Sciences, the organizer of market leading events in drug discovery and biologics development, today announced that George Church and Feng Zhang, two world-renowned scientists, will provide the keynote presentations at the Genome Editing Applications conference to be held on March 18-19, 2015 at the Hilton Boston Back Bay, Boston, MA. The Genome Editing Applications conference is the first comprehensive event to focus on the applications of genome editing technologies and genome engineering in therapeutic development, drug discovery and screening and other research applications.

"The emerging applications of genome editing tools hold enormous potential for the development of powerful life saving therapies. Genome editing technologies also offer significant advantages in drug discovery, target validation, screening and other pharmaceutical research applications, including development of gene therapies, cell therapies and immunotherapy. In George Church and Feng Zhang, we are excited to have two of the most respected leaders in the field to share their insights on current and future technologies and applications in genome editing and genome engineering, “said Michael Keenan, Conference Director, IBC Life Sciences.

The event features a compelling program that enables delegates to:
  • • Learn about therapeutic applications of genome editing in cardiovascular disease, gene therapy, stem cell therapy, CART cell immunotherapy, hemophilia B and other advances in in vivo genome editing
  • • Gain an in-depth update on the latest technology advances and applications of CRISPR-Cas9 including a discussion of off-target issues, delivery to cells/tissues, improving specificity and multi-genic alterations
  • • Apply genome editing as a research and drug discovery tool in target identification and validation, genome-scale screening, gene targeting, cell line validation and transgenic animal models
  • • Compare the advantages and disadvantages of CRISPRs, ZFNs, and TALENs for various applications and discover ways to navigate the IP landscape of genome editing technologies for your own projects
For more information about the Genome Editing Applications conference and how to register, visit the webpage.

About the Genome Editing Applications conference
IBC’s Genome Editing Applications conference will showcase the most up-to-date therapeutic and biomedical applications emerging using CRISPRs, ZFNs, TALENs, AAVs and other genome engineering technologies. From validation of targeted cell lines and development of transgenic animal models to therapeutic uses in cell therapy, gene therapy and immunotherapy, this event will also highlight applications in drug target identification/validation and lead discovery and explore how these technologies are being used for whole-genome and functional screening as well as basic research applications. A special emphasis on CRISPR will highlight the design of novel CRISPR constructs and discuss practical aspects of CRISPR including off-target effects, how to improve specificity and delivery to specific cell types, including potential applications in multi-genic alterations. By attending this applications-focused conference you will learn about advances in all of the latest genome editing technologies, including comparisons, advantages and disadvantages of each. You will also learn how to position your company for success in genome editing in the face of the still-evolving IP landscape of CRISPR and other genome editing approaches.

About IBC Life Sciences
IBC Life Sciences, a division of Informa, is your connection to the life sciences industry. Through conferences, webinars, podcasts and its suite of integrated marketing solutions, IBC Life Sciences delivers expert knowledge, valuable connections and customized offerings so customers can meet their goals. www.IBCLifeSciences.com


Share this article with your social network, just click below to share now!


No comments :

Post a Comment